clinical endpoint is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-03. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
== Scoring == The LP-IR score ranges from 0 (most insulin-sensitive) to 100 (most insulin-resistant). It's calculated by weighting the six parameters, which are more strongly correlated with insulin resistance than individual lipid measures like triglycerides or HDL cholesterol alone. Results are typically categorized:
=== As an androgen === DHEA and other adrenal androgens such as androstenedione, although relatively weak androgens, are responsible for the androgenic effects of adrenarche, such as early pubic and axillary hair growth, adult-type body odor, increased oiliness of hair and skin, and mild acne. DHEA is potentiated locally via conversion into testosterone and dihydrotestosterone (DHT) in the skin and hair follicles. Women with complete androgen insensitivity syndrome (CAIS), who have a non-functional androgen receptor (AR) and are immune to the androgenic effects of DHEA and other androgens, have absent or only sparse/scanty pubic and axillary hair and body hair in general, demonstrating the role of DHEA and other androgens in body hair development at both adrenarche and pubarche.
Piracetam is not a vitamin, mineral, amino acid, herb or other botanical, or dietary substance for use by humans to supplement the diet by increasing the total dietary intake. Further, piracetam is not a concentrate, metabolite, constituent, extract or combination of any such dietary ingredient. [...] Accordingly, these products are drugs, under section 201(g)(1)(C) of the Act, 21 U.S.C. § 321(g)(1)(C), because they are not foods and they are intended to affect the structure or any function of the body. Moreover, these products are new drugs as defined by section 201(p) of the Act, 21 U.S.C. § 321(p), because they are not generally recognized as safe and effective for use under the conditions prescribed, recommended, or suggested in their labeling.
Sanders influenced the environmental policy goals of the Biden administration as described before Biden's nomination. Biden's policy team adopted certain details from the Biden–Sanders Unity Task Forces' climate recommendations. After Biden was elected president, Sanders became the subject of speculation over a potential appointment as Labor Secretary, which was supported by several progressive groups, such as the Sunrise Movement. For his part, Sanders said that he would accept Biden's nomination if it was offered, but Boston mayor Marty Walsh was chosen for the position instead. When announcing Walsh's nomination, Biden confirmed that he had discussed the position with Sanders, but the two agreed that Sanders's resignation from the Senate and the ensuing special election would have put the Democrats' slim Senate majority at risk. On February 23, 2021, Sanders became the first senator in the Democratic caucus to oppose one of Biden's cabinet picks when he voted against Tom Vilsack's confirmation as Agriculture Secretary, citing concerns about Vilsack's past work as a lobbyist and ties to large corporations. In 2022, Sanders signed letters to Vilsack and Solicitor General of the United States Elizabeth Prelogar asking them to support the California farm animal welfare law Proposition 12 against a challenge to the law the National Pork Producers Council filed before the Supreme Court.
=== Protein-polymer hybrid supramolecular structures === Polymer-protein conjugates can also form a higher ordered supramolecular structure via self-assembly of amphiphilic polymers into micelles and microcapsules, which is a potential strategy to generate drug delivery systems. Such systems have the innate advantage of rapid preparation, a high drug loading capacity, ease of surface decoration, and the potential to be stimuli responsive.
Sources: en.wikipedia.org
Killed Arpad Horvath (75) at Meadow Park facility in London, Ontario Injected Sandra Towler (77) "with intent to murder" at a retirement home in Paris, Ontario Injected Beverly Bertram (68) "with intent to murder" at a private residence in Ingersoll, Ontario
Aristotle applies his theory of hylomorphism to living things. He defines a soul as that which makes a living thing alive. Life is a property of living things, just as knowledge and health are. Therefore, a soul is a form—that is, a specifying principle or cause—of a living thing. Furthermore, Aristotle says that a soul is related to its body as form to matter. Hence, Aristotle argues, there is no problem in explaining the unity of body and soul, just as there is no problem in explaining the unity of wax and its shape. Just as a wax object consists of wax with a certain shape, so a living organism consists of a body with the property of life, which is its soul. On the basis of his hylomorphic theory, Aristotle rejects the Pythagorean doctrine of metempsychosis, ridiculing the notion that just any soul could inhabit just any body. According to Timothy Robinson, it is unclear whether Aristotle identifies the soul with the body's structure. According to one interpretation of Aristotle, a properly organized body is already alive simply by virtue of its structure. However, according to another interpretation, the property of life—that is, the soul—is something in addition to the body's structure. Robinson uses the analogy of a car to explain this second interpretation. A running car is running not only because of its structure but also because of the activity in its engine.
=== Predators === The species Hydra oligactis is preyed upon by the flatworm Microstomum lineare. Some Coleps sp. have also been observed to attack Hydra polyps in groups, with them attacking Hydras' tentacles first before consuming the entire polyps. Some other common predators include carnivorous or omnivorous fishes such as guppies, bettas, and gouramis.
==== Antibody-drug conjugates ==== Antibody-drug conjugates (ADCs) comprise an antibody, drug and a linker between them. The antibody will be targeted at a preferentially expressed protein in the tumour cells (known as a tumor antigen) or on cells that the tumor can utilise, such as blood vessel endothelial cells. They bind to the tumor antigen and are internalised, where the linker releases the drug into the cell. These specially targeted delivery vehicles vary in their stability, selectivity, and choice of target, but, in essence, they all aim to increase the maximum effective dose that can be delivered to the tumor cells. Reduced systemic toxicity means that they can also be used in people who are sicker and that they can carry new chemotherapeutic agents that would have been far too toxic to deliver via traditional systemic approaches. The first approved drug of this type was gemtuzumab ozogamicin (Mylotarg), released by Wyeth (now Pfizer). The drug was approved to treat acute myeloid leukemia. Two other drugs, trastuzumab emtansine and brentuximab vedotin, are both in late clinical trials, and the latter has been granted accelerated approval for the treatment of refractory Hodgkin's lymphoma and systemic anaplastic large cell lymphoma.
Sources: en.wikipedia.org
=== 2022–present: Potential seventh studio album, Kinney health issues and cancelled tour === In an April 2022 interview, vocalist William DuVall revealed that he was "sure" Alice in Chains would begin working on their seventh studio album later in the year: We had a lot of time imposed on us and I think we're going through this period of catching up on things that we had planned for 2020 [and] 2021, and we're all finally getting to do that now. So, it's kind of like a stopgap and we're just dealing with all of these stockpiled projects that we had planned a few years back. So once we get back up to speed with things and we get these dates underway in late summer, I'm sure it will spark a whole bunch of ideas for the next Alice in Chains studio album. However, in March 2023, DuVall stated there were "no plans" for new Alice in Chains music. In February 2025, the band announced appearances at Welcome to Rockville in Daytona Beach, Florida, Sonic Temple in Columbus, Ohio, and MMR*B*Q, a festival hosted by WMMR in Camden, New Jersey, alongside three other headlining performances with Chained Saint, a thrash metal band from Florida. The tour was set to kick off at Mohegan Sun Arena in Montville, Connecticut on May 8, when Kinney suffered a medical emergency during soundcheck that evening. The band described the event as "non-life threatening" but were forced to cancel the show; two days later, the entire tour was scrapped.
=== Controlling pore size === The microstructural wavelength (average pore + wall thickness) can be described as a function of the solidification velocity v (λ= Av−n) where A is dependent on solids loading. There are two ways then that the pore size can be controlled. The first is to change the solidification speed that then alters the microstructural wavelength, or the solids loading can be changed. In doing so, the ratio of pore size to wall size is changed. It is often more prudent to alter the solidification velocity seeing as a minimum solid loading is usually desired. Since microstructural size (λ) is inversely related to the velocity of the freezing front, faster speeds lead to finer structures, while slower speeds produce a coarse microstructure. Controlling the solidification velocity is, therefore, crucial to being able to control the microstructure.
Ro64-6198 is an opioid drug used in scientific research. It acts as a potent and selective agonist for the nociceptin receptor, also known as the ORL-1 (opiate receptor like-1) receptor, with over 100x selectivity over the other opioid receptors. It produces anxiolytic effects in animal studies equivalent to those of benzodiazepine drugs, but has no anticonvulsant effects and does not produce any overt effects on behaviour. However it does impair short-term memory, and counteracts stress-induced anorexia. It also has antitussive effects, and reduces the rewarding and analgesic effects of morphine, although it did not prevent the development of dependence. It has been shown to reduce alcohol self-administration in animals and suppressed relapses in animal models of alcoholism, and ORL-1 agonists may have application in the treatment of alcoholism. Ro64-6198 was able to be recognised as a discriminative stimulus by rats distinct from other opioid receptor ligands, but was not able to produce the conditioned place preference thought to be indicative of addictive potential. Consequently, while the role of ORL-1 receptors in the body is complex and remains poorly understood, Ro64-6198 has demonstrated multiple pharmacological actions and has been very useful in the study of the ORL-1 receptor system, especially in relation to anxiety and anorexia; however, due to poor oral bioavailability, Ro 64-6198 will most likely not be pursued clinically. Studies in primates showed it to have analgesic effects but without producing respiratory depression or reinforcing effects.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
它促进未成熟T细胞分化并增强成熟T细胞的增殖与细胞因子分泌。这些作用有助于放大抗原特异性免疫应答。